rheumatoid arthritis – media

Immunovia’s IMMray Test for RA Shows Promising Results

Rheumatoid arthritis (RA) gets a new parameter to be detected via the IMMray blood test developed by Immunovia, a Swedish company which observed promising findings in a clinical study conducted in conjunction with Linköping University.
- Source: The Verdict
- 691
- August 29, 2018
Researches rheumatoid arthritis
Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
- Source: drugdeliverybusiness
- 632
- May 2, 2018
Gilead Market Views rheumatoid arthritis
FDA ‘conflicted’ on Lilly and Incyte’s refiled baricitinib

Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety. A briefing document published ahead of the April 23 advisory committee meeting on baricitinib suggests that Lilly and Incyte’s lightning-fast amendment and refile of the dossier hasn’t added enough data to persuade the FDA to change its stance on the risk of blood clots with the JAK inhibitor.
- Source: Fiercebiotech; new approvals
- 618
- April 24, 2018
baricitinib Eli Lilly FDA rheumatoid arthritis
AbbVie Scores Key Trial Win for RA Drug With One Fatal Event Reported

AbbVie’s investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients. But the drug shows that it is still plagued by some safety concerns.
- Source: Biospace
- 577
- December 21, 2017
Clinical Trials inhibitor Phase rheumatoid arthritis
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active Psoriatic Arthritis

XELJANZ/XELJANZ XR, THE FIRST ORAL JAK INHIBITOR IN THE U.S. FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS, IS NOW APPROVED FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS
- Source: Pfizer
- 520
- December 21, 2017
DMARDs New Approvals rheumatoid arthritis XELJANZ
Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis

Maintaining sufficient vitamin D levels may help to prevent the onset of inflammatory diseases like rheumatoid arthritis, research led by the University of Birmingham has discovered.
- Source: medicalxpress
- 581
- November 21, 2017
inflammatory diseases rheumatoid arthritis vitamin D
Rheumatoid arthritis may raise COPD risk

New research suggests that people with rheumatoid arthritis are more likely to develop chronic obstructive pulmonary disease (COPD), which is a group of lung diseases that damage the airways and cause problems with breathing.
- Source: medicalnewstoday
- 546
- October 27, 2017
COPD Researches rheumatoid arthritis
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly

A legal brawl between two of the world’s largest drug companies could shape the future of a nascent market of copycat drugs that are intended to bring down the cost of the most advanced and expensive medicines.
- Source: Washingtonpost
- 701
- September 22, 2017
biosimilar Johnson & Johnson Pfizer rheumatoid arthritis
First PhIII trial of AbbVie’s upadacitinib a success

AbbVie’s upadacitinib has hit primary and secondary targets in the first late-stage trial of the drug involving patients with moderate-to-severe rheumatoid arthritis (RA).
- Source: Pharmatimes
- 514
- June 9, 2017
Clinical Trials rheumatoid arthritis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.